Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for head and neck cancer patients who Can't take chemo

NCT ID NCT07445048

First seen Mar 05, 2026 · Last updated Jun 12, 2026 · Updated 14 times

Summary

This phase 3 trial tests a new treatment for people with high-risk head and neck cancer who cannot receive the standard chemotherapy drug cisplatin. Participants receive radiation therapy combined with two drugs (nimotuzumab and benmelstobart) to see if this approach improves disease-free survival compared to standard care. The study enrolls 370 adults and follows them for up to 3 years after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai 9th people's hospital

    RECRUITING

    Shanghai, 200011, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

Head and Neck Neoplasms head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.